## ISO 10993-1:2018 (E)

# Biological evaluation of medical devices — Part 1: Evaluation and testing within a risk management process

### Contents

Foreword

#### Introduction

- 1 Scope
- 2 Normative references
- 3 Terms and definitions
- 4 General principles applying to biological evaluation of medical devices
- 5 Categorization of medical devices
  - 5.1 General
  - 5.2 Categorization by nature of body contact
  - 5.2.1 Non-contacting medical devices
  - 5.2.2 Surface-contacting medical devices
  - 5.2.3 Externally communicating medical devices
  - 5.2.4 Implant medical devices
  - 5.3 Categorization by duration of contact
  - 5.3.1 Contact duration categories
  - 5.3.2 Transitory-contacting medical devices
  - 5.3.3 Medical devices with multiple contact duration categories
- 6 Biological evaluation process
  - 6.1 Physical and chemical information for biological risk analysis
  - 6.2 Gap analysis and selection of biological endpoints for assessment
  - 6.3 Biological testing
  - 6.3.1 General
  - 6.3.2 Testing for evaluation
  - 6.3.2.1 Cytotoxicity
  - 6.3.2.2 Sensitization
  - 6.3.2.3 Irritation (including intracutaneous reactivity)
  - 6.3.2.4 Haemocompatibility
  - 6.3.2.5 Material-mediated pyrogenicity
  - 6.3.2.6 Acute systemic toxicity
  - 6.3.2.7 Subacute and subchronic toxicity
  - 6.3.2.8 Chronic toxicity
  - 6.3.2.9 Implantation effects
  - 6.3.2.10 Genotoxicity
  - 6.3.2.11 Carcinogenicity
  - 6.3.2.12 Reproductive and developmental toxicity
  - 6.3.2.13 Degradation
  - 6.3.2.14 Toxicokinetic studies
  - 6.3.2.15 Immunotoxicology

#### 7 Interpretation of biological evaluation data and overall biological risk assessment

#### Annex A (informative) Endpoints to be addressed in a biological risk assessment

- A.1 General
- A.2 Rationale for endpoints in Table A.1

- Annex B (informative) Guidance on the conduct of biological evaluation within a risk management process
  - B.1 Background information
  - B.1.1 General
  - B.1.2 Relationship with other standards, guidance documents and regulatory requirements
  - B.2 Biological evaluation as a risk management practice
  - B.2.1 General
  - B.2.2 The biological evaluation plan
  - B.3 Guidance on risk management
  - B.3.1 Risk assessment
  - B.3.1.1 Introduction
  - B.3.1.2 Risk analysis
  - B.3.1.3 Risk estimation
  - B.3.1.4 Risk evaluation
  - B.3.2 Risk control
  - B.3.3 Evaluation of residual risk acceptability
  - B.3.4 Post production monitoring
  - B.4 Guidance on specific aspects of biological evaluation
  - B.4.1 Material characterization
  - B.4.1.1 Chemical characterization
  - B.4.1.2 Use of chemical characterization data in a biological evaluation
  - B.4.1.3 Proprietary materials formulations
  - B.4.1.4 Physical Characterization
  - B.4.1.5 Effects of manufacturing processes
  - B.4.2 Collection of existing data
  - B.4.3 Device testing considerations
  - B.4.3.1 Tiered approaches to biological testing
  - B.4.3.2 When to do long-term testing (chronic toxicity, reproductive toxicity, degradation and carcinogenicity studies)
  - B.4.3.3 In vitro system pH and osmolality compensation for absorbable materials
  - B.4.4 Biological safety assessment
  - B.4.4.1 Use of clinically relevant data for a risk assessment
  - B.4.4.2 What constitutes "sufficient toxicology data" including dose and route relevance
  - B.4.4.3 Determining the acceptability of the level of leachable (allowable limit) according to ISO 10993-17
  - B.4.4.4 Thresholds of Toxicological Concern (TTC)
  - B.4.4.5 Guidance on mixtures in risk assessment
  - B.4.5 General guidance
  - B.4.5.1 Changes which can require re-evaluation of biological safety
  - B.4.5.2 Good laboratory practice
  - B.4.5.3 Biocompatibility evaluation documentation

#### Annex C (informative) Suggested procedure for literature review

- C.1 Introduction
- C.2 Methodology
- C.2.1 General
- C.2.2 Objective(s)
- C.2.3 Selection criteria for documents
- C.2.4 Assessment of documents
- C.2.5 Critical evaluation of the literature

Page count: 41